leisure time -WSS

leisure time

author：hotspot 2025-09-27 11:58:24 - browse：4

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Flint parents haunted by uncertainty, fears of lead poisoning

WSS

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

2 officers injured in shooting in Orlando, police say

FDA scientists endorse Pfizer/BioNTech Covid

The cancer stories no one wants to hear

A letter from the executive editor: STAT UnitedHealth investigation

A letter from the executive editor: STAT UnitedHealth investigation

focus

leisure time

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Jerome Adams on the need for new antivirals for Covid

Physicians aren't 'burning out.' They're suffering from moral injury

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Pharma showers House GOP doctor with campaign cash

Continuity nursing helped my family in our darkest PICU moments

Study suggests Covid rebound is far more common with Paxlovid than without

The cancer drug shortage isn’t new — and neither are the solutions

Study suggests Covid rebound is far more common with Paxlovid than without

knowledge

After decades in use, heart stents finally beat placebo

2 officers injured in shooting in Orlando, police say

Alnylam reports growth in sales of rare disease treatments

How state and local governments are sidelining science

Heart disease in astronauts blamed on cosmic radiation

How state and local governments are sidelining science

focus

leisure time

leisure time

focus